Navigation Links
YM BioSciences provides update on AeroLEF(TM) clinical development program
Date:1/17/2008

MISSISSAUGA, ON, Jan. 17 /PRNewswire-FirstCall/ - YM BioSciences Inc. (AMEX: YMI, TSX: YM, AIM: YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that it has received a letter from the U.S. Food and Drug Administration (FDA) informing the Company that the Phase II Acute Pain Study (AP5) of AeroLEF(TM) for which FDA clearance was announced on June 27, 2007, upon re-review of data from the IND submission, has been placed on clinical hold. The FDA has requested additional safety information on specific patients in previous clinical studies. The additional requested data is limited to a small group of patients that experienced oxygen desaturation, a class effect of opioids including fentanyl. The Company will conduct a subgroup analysis on these patients. To date, no patients have been dosed in the US AP5 study and there are no other clinical trials involving AeroLEF(TM) currently ongoing.

"We are confident that we can provide the information the FDA has requested in a timely manner," said David Allan, Chairman and CEO of YM BioSciences. "We appreciate that the FDA has to ensure that any risk to patients during clinical trials is minimized and we understand their caution with opioid-based therapeutics."

Dr. Diana Pliura, Executive Vice President, AeroLEF(TM) added, "Data reported in May 2007 from our successful randomized Phase 2b trial demonstrated that patients had a statistical and clinical benefit from AeroLEF(TM). We remain strongly committed to the clinical development of this unique product."

YM BioSciences also reported that it held its scheduled End-of-Phase 2 (EoP2) meeting with the FDA on January 16, 2007 as planned.

YM
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... The third Medical Innovation ... combination products , in particular, drug/device combinations. The current system received a score of ... Initiative for Patient Centered Innovation (iPCI) of Fairleigh Dickinson University’s ( FDU ) ...
(Date:7/29/2015)... Francisco, CA (PRWEB) , ... July 29, 2015 , ... ... in the morning is quite normal. Although there are a considerable number of terms ... well understood that this post-sleep material is a mixture of mucus, blood cells, skin ...
(Date:7/29/2015)... , ... July 29, 2015 , ... Costello served as ... system to protect the Orange County, Texas area from future storm surge flooding, ... team in determining several potential levee alignment alternatives for providing protection, Costello also balanced ...
(Date:7/29/2015)... , ... July 29, 2015 , ... Nearly everyone has ... diseases. Yet few people realize that a rich source of these cells is teeth—baby ... and teeth that need to be pulled to make room for braces. These ...
Breaking Biology Technology:Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 2What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 3What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 4Preventing Storm Surge Flooding in Houston 2Advanced Oral and Maxillofacial Surgery (AOMS) in Elmhurst, IL Partners with Provia Labs to make Store-A-Tooth™ Dental Stem Cell Banking Available to their Patients 2
... Diplomat Specialty,Pharmacy today announced that Dr. Atheer ... Dr. Kaddis will serve as Vice President of,Managed ... Diplomat Specialty,Pharmacy,s President and CEO, Philip Hagerman. ... Managed Care,expertise we need to further develop competitive, ...
... 22 Laser Energetics,Inc. (Pink Sheets: LNGT) announced ... several medical and dental instrument suppliers regarding,the integration ... dental products. LEI,s BrightStar(TM) Alexandrite laser,s shorter ... system can enhance medical and,dental laser applications. The ...
... Shared Through Dynamic WikiAnswers Q&A ... ... show of support for National,Breast Cancer Awareness Month, Answers.com,s question and ... where breast cancer survivors,friends and family have gathered to ask questions ...
Cached Biology Technology:Diplomat Specialty Pharmacy Hires Vice President of Managed Markets 2Laser Energetics to Integrate BrightStar(TM) Alexandrite Lasers in Medical and Dental Applications 2Laser Energetics to Integrate BrightStar(TM) Alexandrite Lasers in Medical and Dental Applications 3Answers.com's WikiAnswers Supervisors Rallying for National Breast Cancer Awareness Month 2Answers.com's WikiAnswers Supervisors Rallying for National Breast Cancer Awareness Month 3
(Date:7/8/2015)... , July 8, 2015  Trovagene, Inc. (NASDAQ: ... diagnostics, today announced the launch of a study ... Precision Cancer Monitoring℠ (PCM) technology for predicting response ... or a combination of the novel immunotherapy agents ... a PD-1 inhibitor. The 50-patient study will be ...
(Date:7/7/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... commerce market announces a revised version of one of its first ... air on CNBC in New York , ... San Francisco metro areas.    ... ability to replace all the cards in your wallet and keep ...
(Date:6/30/2015)... YORK , June 30, 2015 To bolster ... security provider HYPR Corp. announced today the addition of two ... will serve as board advisor and David Raviv ... the team underscore HYPR Corp.,s commitment to providing the most ... Dimitri Sirota co-founded Layer 7 Technologies, a provider ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... A team led by Johns Hopkins scientists has,found ... the human immune,system's remarkable ability to recognize and ... from a family of genes whose,only apparent function ... genes" ,essentially cut themselves out of the genetic ...
... As public health officials in China brace for a potential ... Chinese New Year on February 9, researchers at Washington University ... that could be an important contributor to the SARS virus' ... virus first jumped from its still unknown animal reservoir to ...
... system (CNS), where it influences neurotransmission to produce intoxication. ... function gene by gene. Symposium proceedings published in the ... the effects of alcohol on what is called "gene ... "All of our cells have exactly the same deoxyribonucleic ...
Cached Biology News:UCSD Discovery Shows How Embryonic Stem Cells Perform 'Quality Control' Inspections 2UCSD Discovery Shows How Embryonic Stem Cells Perform 'Quality Control' Inspections 3New SARS Protein Linked To Important Cell Doorway 2New SARS Protein Linked To Important Cell Doorway 3Alcohol's effects on gene expression in the central nervous system 2Alcohol's effects on gene expression in the central nervous system 3Alcohol's effects on gene expression in the central nervous system 4
... Application: Acridine orange has been used ... in agarose and polyacrylamide gels. Acridine orange ... detect purified DNA in gels with a ... has also been used extensively for cell ...
Miscellaneous: Versatile stain for staining RNA (bluish-purple), DNA (blue), proteins (red) and acid polysaccharides Assay: ~ 95 % Suitab tst: differential staining of nucleic acids and prote...
...
... step procedure (PCR, Exonuclease III digestion and ... day. The typical cloning efficiency using this ... and Benefits: , , Universal - PCR ... vector , High Cloning Efficiency - Typically>80% ...
Biology Products: